ST6GAL1 and neoplasm: If the response of differentially-sialylated tumor cells to cisplatin treatment is indicative of a general protective effect of ST6Gal-I in the presence of cisplatin, then it would be expected that other cell models of cisplatin resistance may exhibit elevated ST6Gal-I expression.